Key points are not available for this paper at this time.
The awareness of late side effects in long-term survivors of primary bone cancers should encourage longer follow-up.
Longhi et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: